市場調查報告書
商品編碼
1145459
醫藥品無菌實驗的全球市場:現狀分析與預測(2022年~2028年)Pharmaceutical Sterility Testing Market: Current Analysis and Forecast (2022-2028) |
全球醫藥品無菌實驗的市場規模在預測期間內預計將以以約9%的顯著速度增長。推動市場增長的主要因素包括人口增長對有效藥物的需求持續增加、疾病流行率上升等。
本報告提供全球醫藥品無菌測試市場調查,提供市場概要,按市場規模和預測,趨勢,促進因素·阻礙因素,樣品·各類型·各地區的分析,及企業簡介等資訊。
The global pharmaceutical sterility testing market is expected to grow at a significant rate of around 9% during the forecast period. Sterilization may be defined as the statistically complete destruction of all microorganisms including the most resistant bacteria and spores. The continuously rising demand for effective medicines due to the increasing population and rising disease prevalence among them are important factors for the growth of pharmaceutical sterility testing. For instance, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Furthermore, strict government regulation on microbial control and good manufacturing process also contributes to the market growth of the pharmaceutical sterility testing industry.
Pacific Biolabs, STRERIS Corporation, Boston Analytical, Gibraltar Laboratories, Sartorius AG, SolviasAG, SGS AG, Toxikon inc., Merck KGaA, and Charles River Laboratories International Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Based on the sample, the market has been categorized into sterile drugs, medical devices, and biologics & therapeutics. The sterile drugs category is expected to witness a higher CAGR during the forecast period. This is mainly due to these drugs directly coming in the contact with the internal body organs and the aftermath of the contaminated drugs can be severe. Furthermore, the rising demand for injectable drugs due to their high absorption in the body is also attributed to the segmental growth of sterile drugs.
Based on the type, the market has been categorized into instruments, kits & reagents, and services. Among them, the service segment is expected to have significant growth in the market. The companies are also providing new services in the sterility testing market catalyzing the segmental growth in the market. For instance, in October 2019, Alcami Corporation launched a rapid sterility offering, a service that leverages cutting-edge microbiological testing technology to deliver significantly faster-testing results to clients.
For a better understanding of the market adoption of the pharmaceutical sterility testing industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. In 2020, North America held a significant share of the global pharmaceutical sterility testing market. This is mainly attributed to the high investment in the healthcare and pharmaceutical sectors coupled with the strict guidelines on the good manufacturing process. For instance, $192 million for coronavirus research and medical countermeasures from the government's Plan to Mobilize Science
The global pharmaceutical sterility testing market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.